Merck & Co. (MRK) : Manufacturers Life Insurance Company The reduced its stake in Merck & Co. by 3.02% during the most recent quarter end. The investment management company now holds a total of 7,656,654 shares of Merck & Co. which is valued at $485,049,031 after selling 238,070 shares in Merck & Co. , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Merck & Co. makes up approximately 0.71% of Manufacturers Life Insurance Company The’s portfolio.
Other Hedge Funds, Including , Investec Asset Management Ltd reduced its stake in MRK by selling 2,202 shares or 1.85% in the most recent quarter. The Hedge Fund company now holds 117,082 shares of MRK which is valued at $7,417,145. Merck & Co. makes up approx 0.04% of Investec Asset Management Ltd’s portfolio.I.g. Investment Management Ltd. reduced its stake in MRK by selling 275,481 shares or 6.66% in the most recent quarter. The Hedge Fund company now holds 3,859,871 shares of MRK which is valued at $246,491,362. Merck & Co. makes up approx 0.95% of I.g. Investment Management Ltd.’s portfolio.Mizuho Trust Banking Ltd. boosted its stake in MRK in the latest quarter, The investment management firm added 8,690 additional shares and now holds a total of 4,478,854 shares of Merck & Co. which is valued at $258,205,933. Merck & Co. makes up approx 0.77% of Mizuho Trust Banking Ltd.’s portfolio.Kanawha Capital Management reduced its stake in MRK by selling 57 shares or 0.23% in the most recent quarter. The Hedge Fund company now holds 24,426 shares of MRK which is valued at $1,432,829. Merck & Co. makes up approx 0.23% of Kanawha Capital Management’s portfolio.
Merck & Co. opened for trading at $62.7 and hit $62.98 on the upside on Thursday, eventually ending the session at $62.9, with a gain of 0.18% or 0.11 points. The heightened volatility saw the trading volume jump to 65,44,694 shares. Company has a market cap of $173,932 M.
On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $0.91. The company had revenue of $9844.00 million for the quarter, compared to analysts expectations of $9782.80 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.86 EPS.
Investors should note that on Jul 26, 2016, Merck & Co. announced a cash dividend of $0.4600. The company’s management has announced Sep 13, 2016 as the ex-dividend date and fixed the record date on Sep 15, 2016. The payable date has been fixed on Oct 7, 2016.
Many Wall Street Analysts have commented on Merck & Co.. Credit Suisse Upgraded Merck & Co. on Aug 8, 2016 to ” Outperform”, Price Target of the shares are set at $73.Company shares were Reiterated by Deutsche Bank on Aug 8, 2016 to “Hold”, Firm has raised the Price Target to $ 59 from a previous price target of $58 .
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.